EpiPen maker Mylan is facing a Federal Trade Commission (FTC) probe into whether or not it improperly acted to prevent competition from generic alternatives to its flagship product, Bloomberg reports. (fortune.com)
Since biosimilars are so new to the U.S. market (there have been just five total approved here since 2015), it's been hard to gauge whether or not they can make a formidable dent in high drug prices by offering generic alternatives to branded treatments. (fortune.com)
The change will delay the entry of generic alternatives and, as acknowledged by Prime Minister Stephen Harper, will raise health care costs across the country (estimates run into the billions). (slaw.ca)